- Five clinical-stage product candidates on track for multiple clinical data updates in 2023 - Cash, cash equivalents and marketable securities sufficient to fund operations into the first half of 2025 - 4D-310 Phase 1/2 clinical trial eligible patient population expanded to include females with

EMERYVILLE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that management will participate in the following upcoming investor

EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, reported first quarter 2022 financial results and provided corporate updates.

EMERYVILLE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that management will participate in the 2022 Bank of America

EMERYVILLE, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT) (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that the first patient has been dosed in its Phase 1/2 clinical

Provided clinical data updates on three programs, including first clinical data on 4D-310 for Fabry disease and 4D-125 and 4D-110 for inherited retinal dystrophies, each demonstrating preliminary evidence of clinical activity Advanced two additional programs into clinical development: R100

EMERYVILLE, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies announced that Professor David Schaffer, Ph.D.

EMERYVILLE, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) --  4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will participate in the 11 th Annual SVB Leerink Global

Following discontinuation of ERT, AGA activity was stable at 14-fold mean normal level through week 37 (Patient 1) and stable at 10-fold mean normal levels through week 20 (Patient 3) Preliminary clinical data suggest encouraging improvement in cardiac imaging endpoints, specifically native T1 for

EMERYVILLE, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced updated interim clinical data from the on-going 4D-310 Phase 1/2 trial in patients